Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on April 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Court preliminarily approved settlement in six consolidated shareholder derivative lawsuits involving Abbott’s infant formula matter.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Court preliminarily approved settlement in six consolidated shareholder derivative lawsuits involving Abbott’s infant formula matter
- Lawsuits target certain current and former Abbott directors and officers
- Final settlement hearing and shareholder notice process now scheduled
- Exhibit 99.1 contains proposed settlement terms and shareholder appearance rights
Item EX-99.1 · Exhibit EX-99.1
- Proposed settlement in infant-formula derivative litigation, still subject to court approval on June 4, 2026
- Abbott to implement corporate-governance reforms and strengthen legal and regulatory oversight
- Attorneys’ fees and expenses capped at $15.85 million, including service awards of up to $15,000 per lead plaintiff
- Approval would dismiss claims with prejudice and release related claims tied to the February 2022 recall and affected facilities
- Defendants deny wrongdoing; settlement avoids further litigation costs, distraction, and uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.